To this end, cohorts of MLL-AF9 AML recipient mice were treated with MMF either from days 1 to 14 (“early”) or from days 14 to 28 (“delayed”) after transplantation (Supplementary Fig. 4b). The gene discussed is KMT2A; the disease is acute myeloid leukemia.